Publication date: Apr 12, 2019
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. , a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the DecisionDx(R)-Melanoma gene expression profile (GEP) test accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node biopsy (SLNB) result.
The study was published in the journal Cancer Medicine and is consistent with previously published prospective and retrospective studies demonstrating the high performance of DecisionDx-Melanoma to predict outcomes, supporting its clinical value to inform patient management decisions.
DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors and has been studied in over 2,900 patients.
The consistent high performance and accuracy demonstrated in these studies, which combined have included over 1,470 patients, provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results.
The Company currently offers tests for patients with cutaneous melanoma (DecisionDx(R)-Melanoma, DecisionDx(R)-CMSeq; www. SkinMelanoma. com) and uveal melanoma (DecisionDx(R)-UM, DecisionDx(R)-PRAME and DecisionDx(R)-UMSeq; www. MyUvealMelanoma. com), with programs in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma.
|disease||MESH||squamous cell carcinoma|
|disease||DOID||squamous cell carcinoma|
- Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
- Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma.
- The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study.
- Wide local excision prior to sentinel lymph node biopsy for primary melanoma of the head and neck.